PharmEasy (API Holdings): FY26 loss cut 67% to ₹520 crore
Independent report content
| FY26 LOSS | About ₹520 crore, down 67% from about ₹1,572 crore in FY25 (annual report, as reported by Medianama and Inc42) |
|---|---|
| FY26 REVENUE | About ₹6,618.5 crore (+12.7%) per Medianama and Inc42; another source gives about ₹6,869 crore against ₹6,010 crore in FY25 |
| SEGMENTS | B2B revenue ₹4,082 crore with an EBITDA loss of ₹3.6 crore · B2C PharmEasy app revenue ₹1,335 crore with an EBITDA loss of ₹44 crore |
| Q3 FY26 | Reported EBITDA-positive |
| TOTAL FUNDING | About US$688m over 11 rounds (Tracxn) |
| VALUATION | Peak about US$5.6bn (2021); later reset to about US$710m (third-party report); unlisted quotes differ |
| IPO | A ₹6,250 crore draft prospectus from 2021 lapsed; no 2026 IPO or rights issue found |
| FOUNDERS | Dharmil Sheth, Dhaval Shah and Hardik Dedhia |
| THE ACCESS POINT PharmEasy (API Holdings) shares trade in the unlisted market. Unlisted quotes are unofficial and vary by marketplace. |
|---|
Executive decision summary
| THE BOTTOM LINE PharmEasy is India's largest online pharmacy group, and it also distributes medicines to chemists, runs diagnostics and owns a controlling stake in listed Thyrocare. It was valued at about US$5.6bn in 2021, then reset to roughly US$710m after losses and an unsuccessful IPO attempt. In FY26 it cut its loss by two-thirds to about ₹520 crore on revenue near ₹6,600 crore, and reported an EBITDA-positive quarter. The B2B arm is now at about break-even at EBITDA; the consumer app still loses money. A new IPO has not been announced. |
|---|
| WHICH INVESTOR Fits you IF you want a turnaround in Indian healthtech where losses are shrinking fast. Look elsewhere IF you want a clean balance sheet: debt and past rights issues still weigh on the group. |
|---|
| COMFORT FIT PharmEasy = a medicines wholesaler to chemists plus a consumer app, plus a lab chain through Thyrocare. Apollo Pharmacy, MedPlus, Tata 1mg = rivals. Thyrocare = the listed lab subsidiary, which gives a market price for part of the group. |
|---|
| THE RUPEIA NUMBER 67%. The fall in the FY26 loss, from about ₹1,572 crore to about ₹520 crore. |
|---|
1 CLAIM REGISTER: EVIDENCE GRADING
A = government or regulator record. B = statutory filing. C = independent press. D = company announcement.
| Claim | Source | Grade | Rupeia assessment |
|---|---|---|---|
| FY26 loss ₹520 crore, −67% | Medianama; Inc42 | B/C | Established as reported from the annual report. |
| FY26 revenue ₹6,618.5 crore (+12.7%) | Medianama; Inc42 | B/C | Another source gives ₹6,869 crore; definitions differ. |
| B2B ₹4,082 crore with ₹3.6 crore EBITDA loss; B2C ₹1,335 crore with ₹44 crore EBITDA loss | Medianama | B/C | Established. |
| Valuation peak US$5.6bn, later about US$710m | ValueForStartups | C | Undated third-party summary. |
| Total funding about US$688m | Tracxn | C | Reported. |
2 COMPANY OVERVIEW & FOUNDING STORY
PharmEasy was founded in Mumbai in 2015 by Dharmil Sheth, Dhaval Shah and Hardik Dedhia, who began by supplying medicines to local chemists and then built a consumer app. Through acquisitions, including Medlife and a controlling stake in Thyrocare, it became a full-stack healthcare commerce group: it supplies pharmacies, sells directly to patients, runs a diagnostics chain and offers other health services.
The group grew fast on venture money, peaking at about US$5.6bn in 2021. When investor appetite for loss-making consumer-internet businesses collapsed, an IPO drafted at ₹6,250 crore did not proceed. A rights issue in 2023 priced the company at about US$710m, wiping out most of the paper gains for later investors.
Since then, management has focused on the unit economics of the B2B distribution arm and on cutting the cost of acquiring consumers. FY26 was the first year in which both arms were close to EBITDA break-even.
3 TIMELINE
| Date | Event |
|---|---|
| 2015 | Founded in Mumbai |
| 2021 | Peak valuation about US$5.6bn; acquires Medlife and a majority of Thyrocare; files ₹6,250 crore draft IPO |
| 2022–23 | IPO shelved; rights issue resets valuation to about US$710m |
| FY25 | Loss about ₹1,572 crore |
| Q3 FY26 | EBITDA-positive quarter reported |
| FY26 | Loss ₹520 crore; revenue about ₹6,600 crore |
4 FUNDING, VALUATION RESET AND CAPITAL STRUCTURE
| Item | Detail | Amount | Comment |
|---|---|---|---|
| Total funding | 11 rounds | ~US$688m | Tracxn, from 96 investors |
| 2021 peak | Series F | Valuation ~US$5.6bn | Undated summary |
| 2023 | Rights issue | Valuation ~US$710m | Down round; about 87% below peak |
| IPO | 2021 draft | ₹6,250 crore | Lapsed; no new filing found |
A drop from US$5.6bn to US$710m is an 87% write-down, one of the largest in Indian internet. Investors who joined in 2021 were heavily diluted or marked down; those who joined at the reset price have seen the loss shrink.
| RUPEIA CALCULATION US$5.6bn to US$710m is a 87% fall. At ₹96.5 per US$, US$710m is about ₹6,850 crore, close to one year of revenue (₹6,600 crore), so the group is valued at about 1.0x sales. |
|---|
5 FINANCIAL FORENSICS
| Metric | FY25 | FY26 | Change |
|---|---|---|---|
| Consolidated loss | ~₹1,572 crore | ~₹520 crore | −67% |
| Consolidated revenue (Medianama basis) | ~₹5,873 crore (derived) | ~₹6,618.5 crore | +12.7% |
| Loss as % of revenue | ~27% | ~7.9% | Rupeia calculation |
| B2B revenue / EBITDA | n/a | ₹4,082 crore / −₹3.6 crore | About break-even |
| B2C app revenue / EBITDA | n/a | ₹1,335 crore / −₹44 crore | −3.3% margin |
The improvement came from cutting discounts and marketing in the consumer app and from B2B scale. B2B is 62% of revenue at a near-zero EBITDA margin, which is normal for a distributor: the profit is small, the volume is large and the working capital is heavy.
| RUPEIA CALCULATION B2C EBITDA of −₹44 crore on ₹1,335 crore is −3.3%; B2B EBITDA of −₹3.6 crore on ₹4,082 crore is −0.1%. Combined, the two named segments lose about ₹48 crore at EBITDA, yet the group loss is ₹520 crore: the gap of about ₹470 crore is interest, depreciation, amortisation of acquired assets and other costs, and is the part to watch. |
|---|
6 BUSINESS MODEL & UNIT ECONOMICS
PharmEasy has four operating units with very different economics.
| Line | How it earns | Pressure point |
|---|---|---|
| B2B distribution (supply to chemists) | Thin trade margin on large volumes; credit to chemists | Receivables; competition from wholesalers |
| B2C pharmacy app | Margin on prescriptions and OTC; delivery fees | Discounts; customer acquisition cost |
| Diagnostics (Thyrocare, listed subsidiary) | Test fees and franchise income | Competition from Dr Lal PathLabs and others |
| Other health services | Teleconsultation and digital health | Small |
Thyrocare gives the group a listed asset with a public price, which supports the balance sheet but also makes minority shareholders' interests part of the governance picture.
7 MARKET & COMPETITIVE ANALYSIS
| Peer | Status | Position |
|---|---|---|
| Apollo 24/7, Apollo Pharmacy | Listed parent | Largest offline and online pharmacy network |
| MedPlus Health Services | Listed | Pharmacy chain in the south |
| Tata 1mg | Private (Tata Digital) | Online pharmacy and labs |
| Thyrocare, Dr Lal PathLabs, Metropolis | Listed | Diagnostics peers |
| Zepto, Blinkit | Listed / private | Fast delivery of OTC and medicines |
No peer combines distribution, retail and diagnostics at this scale. Valuation comparisons use pharmacy chains (price to sales near 1x) and diagnostics (price to earnings above 30x), so the group is a sum of different multiples.
8 WHY THE B2B ARM MATTERS MORE THAN THE APP
It generates about 62% of revenue and is at EBITDA break-even.
Its customers are chemists who rely on credit and delivery; switching is slow.
It supplies the consumer arm with inventory at low cost.
Distribution scale is hard to build quickly: wholesalers have long relationships with manufacturers.
The consumer app is the visible brand, but profit, if any, will come from distribution plus diagnostics.
9 DEBT, RIGHTS ISSUES AND WHO PAYS
The 2023 rights issue and earlier large venture rounds mean the capital structure carries preference rights for some investors. Investors should read the notes in the annual report for the order of repayment and conversion terms. A new IPO would require clean-up of these preferences and an audited multi-year record of profit.
10 VALUATION ARITHMETIC
| Valuation | ₹ crore (₹96.5/US$) | x FY26 revenue (₹6,618.5 crore) |
|---|---|---|
| US$710m (2023 reset) | ~6,850 | 1.0x |
| US$1.0bn | ~9,650 | 1.5x |
| US$5.6bn (2021 peak) | ~54,000 | 8.2x |
Rupeia calculation. Unlisted marketplaces show different prices and share counts, so they are not used here.
11 SCENARIO ANALYSIS
| Scenario | Probability | What happens |
|---|---|---|
| Bull | 25% | Group reaches EBITDA and cash breakeven; IPO refiled at US$1.2–1.5bn |
| Base | 45% | Slow improvement; valuation remains near US$0.7–1bn |
| Bear | 30% | Debt and consumer costs stall the turnaround; another recapitalisation |
12 RISK ANALYSIS: RED FLAG LEDGER & KILL CONDITIONS
| Risk | Severity | Kill condition |
|---|---|---|
| Leverage and capital structure | High | Further rights issue or down round |
| Thin margins in B2B | High | Distribution margin cut by suppliers |
| Consumer-app competition | Medium | Quick-commerce players take OTC and pharmacy share |
| Regulation of e-pharmacy | Medium | Rules restricting online sales |
| IPO uncertainty | Medium | No filing by 2027 |
13 INVESTOR CLASS ANALYSIS
HNIs and family offices
Unlisted prices are unofficial. Anchor on a revenue multiple near 1x, and ask whether the share class carries preferences.
Institutions
The shareholder base includes global funds that have written down; exit pressure may shape any IPO.
NRIs
NRIs can hold unlisted Indian shares under FEMA pricing and reporting rules; repatriation depends on the account route used.
14 THE EARLY SIGNAL: EVENTS TO WATCH
| When | Event |
|---|---|
| Early 2027 | FY27 quarterly results; EBITDA trend |
| 2027 | Any IPO refiling or pre-IPO round |
| Ongoing | Thyrocare results and any stake changes |
15 RUPEIA FINAL INDEPENDENT VIEW
PharmEasy has done what turnarounds need: it cut losses by two-thirds while growing revenue. The group is still lossmaking, it carries a heavy capital structure, and an IPO is not yet in view.
| THE RUPEIA NUMBER 67%. The fall in the FY26 loss, from about ₹1,572 crore to about ₹520 crore. |
|---|
| RUPEIA VERDICT A credible recovery at a much lower price. Still a turnaround, not a quality compounder. |
|---|
Frequently asked questions
What was PharmEasy's FY26 loss?
About ₹520 crore, down 67% from about ₹1,572 crore.
What is its revenue?
About ₹6,618.5 crore in FY26 per Medianama and Inc42; another source gives ₹6,869 crore.
Is the B2B arm profitable?
It was at about break-even at EBITDA in FY26 (loss of ₹3.6 crore on ₹4,082 crore).
What is its valuation?
Reset to about US$710m in 2023 from a US$5.6bn peak in 2021.
Will PharmEasy list?
No new IPO has been announced.
Source log
Medianama: PharmEasy parent trims FY26 loss to ₹520 crore
Inc42: API Holdings FY26 loss declines 67%
Tracxn: PharmEasy
Planify: API Holdings FY26 vs FY25
UnlistedZone: API Holdings FY26 analysis
ValueForStartups: PharmEasy investor report
Wikipedia: PharmEasy
| DISCLAIMER This report is independent research by Rupeia Investments Co. built only from public sources as of the date shown. It is not an offer, solicitation or investment advice, and it is not a recommendation to buy or sell any security. Private-company figures are drawn from filings and media reports and may be revised. Unlisted and private-market investments are illiquid and carry a risk of total loss. Investors should take independent advice. |
|---|
